Coronavirus company news summary – LooK SPOT antigen test receives CE-IVD clearance for Europe – Cue’s molecular, point-of-care Covid-19 tests now available in ten US states

20 January 2021 (Last Updated January 20th, 2021 11:01)

Applied DNA Sciences has announced that its Linea™ Covid-19 Assay Kit is able to detect multiple Covid-19 variants. The variants were identified as part of the safeCircleTM pooled surveillance testing service provided by the company through its Assay Kit.

Laipac Technology, an IoMT (Internet of Medical Things) developer, has recieved CE IVD clearance for its LooK SPOT Covid-19 antigen rapid test. The LooK test is a smartphone-based diagnostic device with a lateral flow immunoassay that detects nucleocapsid protein from SARS-CoV-2 nasal swab samples.

Cue Health, a medical diagnostic products manufacturer, has announced that its molecular, point-of-care Covid-19 tests will be distributed across five additional states, including Colorado, Rhode Island, Pennsylvania, Minnesota, and Utah, as part of the joint $481m programme initiated by the US Department of Health and Human Services (HHS) and the Department of Defence (DOD). The tests are already distributed across AlaskaFloridaLouisianaNew Jersey and Texas.